Introduction {#s1}
============

The 5-hydroxytryptamine-3, or serotonin (5-HT) type 3, receptor is an ionotropic receptor and a member of the Cys-loop family of pentameric ligand-gated ion channels, and thereby, differs from G-protein-coupled serotonin receptors ([@B53]). The 5-HT type 3 receptor (5-HT~3~R) is similar in structure and function to other members of the pentameric ligand-gated ion channel family, including cation-selective nicotinic acetylcholine (nACh) receptors (nAChRs) and anion-selective GABA~A~ and glycine receptors. Malfunction in these receptors has been linked to several neurologic disorders ([@B35]). Together, they are responsible for fast neurotransmission in the central and peripheral nervous system ([@B54]) and are involved in virtually all brain functions ([@B27]).

To date, five different 5-HT~3~ subunits have been identified (5-HT~3A~ -- 5-HT~3E~). The first subunit to be cloned, 5-HT~3A~ ([@B38]), is the only subunit among these that can form functional homo-oligomeric receptors on the cell membrane when expressed in *Xenopus* oocytes or cell lines ([@B29]). Introduction of the 5-HT~3B~ subunit yields functional heteromers with altered properties compared with the homo-oligomer and with heteromer function more closely resembling the functional responses observed in native tissues ([@B29]; [@B15]). When compared with 5-HT~3A~, the 5-HT type 3AB receptor (5-HT~3AB~R) differs in agonist concentration-response curves, shows increased single-channel conductance and desensitization, and an altered current-voltage relationship ([@B15]; [@B17]; [@B34]).

The 5-HT~3~R is widely distributed in the central and peripheral nervous systems and on extraneuronal cells, such as monocytes, chondrocytes, T-cells, and synovial tissue ([@B21]). In the periphery, 5-HT~3~Rs are found in the autonomic, sensory, and enteric nervous systems ([@B20]), where they are involved in regulating gastrointestinal functions, such as motility, emesis, visceral perception, and secretion ([@B43]; [@B37]). The highest density of 5-HT~3~Rs in the central nervous system is in the hindbrain, particularly the dorsal vagal complex involved in the vomiting reflex, and in limbic structures, notably the amygdala, hippocampus, nucleus accumbens, and striatum ([@B32]; [@B40]). Substantial 5-HT~3B~ expression was identified in the human brain with high levels in the amygdala, hippocampus, and the nucleus caudate ([@B17]; [@B55]). A high amount of 5-HT~3~Rs are found on presynaptic nerve fibers ([@B42]; [@B39]), through which they can modulate the release of other neurotransmitters, such as dopamine, cholecystokinin, GABA, substance P, and acetylcholine ([@B8]; [@B20]). Owing to its involvement in many brain functions, the 5-HT~3~R represents an attractive therapeutic target.

5-HT~3~R antagonists are used to effectively treat patients experiencing irritable bowel syndrome and chemotherapy-/radiotherapy-induced and postoperative nausea and vomiting ([@B53]). Some antidepressants ([@B10]; [@B18]) and antipsychotic drugs ([@B47]) also antagonize 5-HT~3~Rs, which, together with other preclinical and clinical studies, suggests the relevance of 5-HT~3~R antagonism for treating psychiatric disorders ([@B57]; [@B5]). We recently discovered that bupropion (Bup), another antidepressant, antagonizes 5-HT type 3A receptors (5-HT~3A~Rs) ([@B45]).

Bupropion was first approved as an "atypical" antidepressant over 30 years ago, and today it is one of the most commonly prescribed antidepressants. Despite its recognized clinical efficacy for both depression and smoking cessation, a comprehensive picture of how bupropion modulates neurotransmission is still emerging. Bupropion's therapeutic effect is thought to be mediated by the blocked reuptake of dopamine and norepinephrine ([@B51]) and the noncompetitive inhibition of neuronal and muscular AChRs ([@B50]). Most recently, the discovery that bupropion also noncompetitively inhibits 5-HT~3A~Rs ([@B45]) raises the questions of whether this inhibition takes place at clinically relevant concentrations and if bupropion also inhibits heteromeric members of the 5-HT~3~ family. Therefore, we investigated the effect of bupropion and its major metabolite, hydroxybupropion (HydroB), on the function of heteromeric 5-HT~3AB~Rs as compared with the homomeric 5-HT~3A~Rs expressed in *Xenopus* oocytes. Here, we demonstrate that 5-HT~3AB~Rs, like 5-HT~3A~Rs, are dose-dependently inhibited by bupropion and its metabolite. This inhibition is voltage-independent and non--use dependent (i.e., affected by preincubation) and occurs at physiologically relevant concentrations.

Materials and Methods {#s2}
=====================

 {#s3}

### Materials {#s4}

Stock of serotonin (2 mM 5-HT, serotonin creatinine sulfate monohydrate; Acros Organics, New Jersey, NJ) and bupropion (100 mM, Toronto Research Chemicals, Inc., North York, Canada) were prepared in distilled water. Hydroxybupropion (100 mM, Toronto Research Chemicals, Inc., North York, Canada) was dissolved in DMSO. All solutions were made in oocyte ringer solution (OR-2) immediately before conducting experiments.

### Molecular Biology. {#s5}

Complementary DNA encoding the mouse 5-HT~3A~R (AAT37716) containing a V5-tag (GKPIPNPLLGLDSTQ) close to the N-terminus ([@B30]) and the mouse 5-HT~3B~ receptor (NP_064670) in the pGEMHE vector were used for oocyte expression ([@B48]). Plasmids were linearized with the NheI restriction enzyme and in vitro transcribed with the T7 RNA polymerase kit (mMESSAGE mMACHINE T7 Kit; Applied Biosystems/Ambion, Austin, TX). Capped complementary RNA (cRNA) was purified with the MEGAclear Kit (Applied Biosystems/Ambion) and precipitated using 5 M ammonium acetate. cRNA dissolved in nuclease-free water was stored at −80°C.

### *X. laevis* Oocyte Preparation. {#s6}

Oocytes were isolated, enzymatically defolliculated, and stored as previously described ([@B24]). *X. laevis* frogs were handled and maintained following procedures approved by the local animal welfare committee (Institutional Animal Care and Use Committee, IACUC no. 08014, PHS Assurance no. A 3056-01). In brief, the isolated oocytes were incubated with collagenase (collagenase from *Clostridium histolyticum* Type IA; Sigma-Aldrich) for 1 hour in OR-2 (115 mM NaCl, 2.5 mM KCl, 1.8 mM MgCl~2~, 10 mM HEPES, pH 7.5), which was followed by extensive washing with OR-2. Oocytes were then rinsed three times with OR-2 + 2 mM Ca^2+^ for 45 minutes each and maintained in standard oocyte saline medium \[100 mM NaCl, 2 mM KCl, 1 mM MgCl~2~, 1.8 mM CaCl~2~, 5 mM HEPES, pH 7.5, supplemented with 1% Antibiotic-Antimycotic (100×, 10,000 U/ml of penicillin, 10,000 mg/ml of streptomycin and 25 mg/ml amphotericin B; Gibco, Thermo Fisher Scientific), 5% horse serum\] for up to 7 days at 16°C. Oocytes were microinjected with 10 ng of in vitro synthesized cRNA (200 ng/μl) using an automatic oocyte injector (Nanoject II; Drummond Scientific Co., Broomall, PA) up to 48 hours after isolation. For optimal expression of the heteromeric 5-HT~3AB~R, the A and B subunits were coinjected in a 1:3 ratio. This ratio has been shown to be optimal for 5-HT~3AB~R expression because a lower ratio results in 5-HT~3A~R mimicked current response and a higher ratio would impact overall receptor expression ([@B54]; [@B12]).

### Electrophysiology. {#s7}

Two-electrode voltage clamp recordings were performed and analyzed using a TEV-200A amplifier (Dagan Instruments, Minneapolis, MN), a Digidata 1440A data interface (Molecular Devices, Sunnyvale, CA), a MiniDigi 1B (Molecular Devices), and the pClamp 10.7 software (Molecular Devices). Recordings were conducted 1--4 days after microinjection. All experiments were performed at room temperature (22--24°C) and at a holding potential of −60 mV, unless otherwise stated. The oocytes were held in a 250 *µ*l chamber and perfused with OR-2 using gravity flow at an approximate rate of 5 ml/min. Drugs and serotonin were dissolved in the same solution and applied by gravity perfusion. The glass microelectrodes were filled with 3 M KCl and had a resistance of below 2 MΩ. Agonists/antagonists were applied until stable response or desensitization was observed to record maximal current responses.

### Data Analysis. {#s8}

All electrophysiological data were analyzed with pClamp, Origin (OriginLab Corporation, Northampton, MA) and GraphPad Prism 6 (GraphPad SoftwareSoft, La Jolla, CA). Data are represented as the mean ± S.D., and maximal current induced by 5-HT was used as the normalizing standard (100% current response) for other current responses in the same oocyte. Statistical significance was determined with paired or unpaired *t* test (in Origin) with a cutoff for significance of 0.05 (\**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001) or one-way ANOVA followed by Dunnett's multiple comparisons test (in Prism). The 5-HT (agonist stimulation---[eq. 1a](#e1a){ref-type="disp-formula"}), bupropion, or hydroxybupropion (antagonist inhibition---[eq. 1b](#e1b){ref-type="disp-formula"}) concentration dependence on 5-HT~3~ currents was fitted using the variable-slope sigmoidal dose response curve equations:Within these equations, *I*~max~ is the current activated at saturating 5-HT concentration, EC~50~ is the agonist concentration producing 50% of the *I*~max~, IC~50~ is the concentration of antagonist producing 50% inhibition of *I*~max~, X is the logarithm of agonist ([eq. 1a](#e1a){ref-type="disp-formula"}) or antagonist ([eq. 1b](#e1b){ref-type="disp-formula"}) concentration, and *n*~H~ is the Hill coefficient. All figures and graphs were made in Origin and Adobe Illustrator CC 2018.

Results {#s9}
=======

 {#s10}

### Differentiating between 5-HT~3A~R and 5-HT~3AB~R. {#s11}

To evaluate the effect of bupropion and its major metabolite hydroxybupropion ([Fig. 1](#F1){ref-type="fig"}) on homomeric and heteromeric 5-HT~3~ receptors, we expressed 5-HT~3A~Rs and 5-HT~3AB~Rs \[in a 1:3 A to B ratio ([@B54]; [@B12])\] in *Xenopus* oocytes. First, we substantiated the obvious difference between the two receptor types ([Fig. 1](#F1){ref-type="fig"}). The application of the agonist 5-HT to *Xenopus* oocytes expressing 5-HT~3A~Rs ([Fig. 1A](#F1){ref-type="fig"}, top trace) or 5-HT~3AB~Rs ([Fig. 1A](#F1){ref-type="fig"}, bottom trace) elicits a rapid inward current with a concentration-dependent amplitude. The currents resulting from a range of 5-HT concentrations were used to calculate the concentrations that produce a half-maximal response ([Fig. 1B](#F1){ref-type="fig"}), yielding EC~50~ values of 0.80 μM (*n* = 5, Hill slope *n*~H~ = 2.53 ± 0.58) for the 5-HT~3A~R and 4.30 μM (*n* = 8; *n*~H~ = 1.04 ± 0.02) for the 5-HT~3AB~R ([Table 1](#T1){ref-type="table"}). Our EC~50~ values are comparable to those reported previously ([@B30]; [@B36]), with the heteromeric receptor showing a right-shift in potency ([Fig. 1B](#F1){ref-type="fig"}) and fast characteristic desensitization kinetics ([Fig. 1C](#F1){ref-type="fig"}). As reported in the literature, the Hill coefficients are indicative of highly cooperative agonist sites for homopentameric channels and of a single site for heteropentameric channels ([@B52]).

![Comparing 5-HT~3A~Rs to 5-HT~3AB~Rs. (A) Sample traces of 5-HT~3A~ (black) and 5-HT~3AB~ (green) at varying concentrations of 5-HT. (B) Concentration-response curves show a higher potency of 5-HT at 5-HT~3A~Rs as compared with 5-HT~3AB~, as well as a steeper Hill slope. Parameters from these curves: 5-HT~3A~: EC~50~ = 0.8 *µ*M, *n*~H~ = 2.53 ± 0.58, *n* = 5, 5-HT~3AB~: EC~50~ = 4.30 *µ*M, *n*~H~ = 1.04 ± 0.02, *n* = 8. Data are represented as the mean ± S.D. (C) Direct comparison of 5-HT~3A~ and 5-HT~3AB~ inward current evoked by 1 μM 5-HT for 30 seconds.](mol.119.118349f1){#F1}

###### 

EC~50~ (5-HT) and IC~50~ values (bupropion and hydroxybupropion) determined in *X. laevis* oocytes expressing 5-HT~3A~Rs and 5-HT~3AB~Rs.

Data represented as mean ± S.D. of *n* experiments. Statistical significance of A as compared with AB was determined with unpaired *t* test (\**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001). pEC~50~ and pIC~50~ are the negative logarithms of EC~50~ and IC~50~, respectively.

               Agonist             pEC~50~ (μM, Mean ± S.D.)       EC~50~              *n*~H~ (Mean ± S.D.)   *n*
  ------------ ------------------- ------------------------------- ------------------- ---------------------- -----
  5-HT~3A~R    5-HT                6.10 ± 0.02\*\*\*               0.80                2.53 ± 0.58\*\*        5
  5-HT~3AB~R   5.38 ± 0.03\*\*\*   4.30                            1.04 ± 0.02\*\*     4                      
                                                                                                              
               Antagonist          pIC~50~ (μM, mean ± S.D.**)**   IC~50~              *n*~H~ (Mean ± S.D.)   *n*
  5-HT~3A~R    Bupropion           4.06 ± 0.05\*\*\*               87.1                1.28 ± 0.15\*\*\*      5
  5-HT~3AB~R   3.09 ± 0.11\*\*\*   840                             1.78 ± 0.15\*\*\*   7                      
  5-HT~3A~R    Hydroxybupropion    3.95 ± 0.10\*\*\*               113                 1.17 ± 0.14\*\*\*      5
  5-HT~3AB~R   3.28 ± 0.02\*\*\*   526                             1.80 ± 0.16\*\*\*   8                      

### Effect of Bupropion on 5-HT~3A~R and 5-HT~3AB~R. {#s12}

5-HT and a wide range of bupropion concentrations (A: 10--1000 *µ*M; AB: 30--4000 *µ*M) were coapplied to *Xenopus* oocytes expressing homomeric 5-HT~3A~Rs ([Fig. 2A](#F2){ref-type="fig"}, top) or heteromeric 5-HT~3AB~Rs ([Fig. 2A](#F2){ref-type="fig"}, bottom) under two-electrode voltage clamp. 5-HT was applied at a concentration that elicits approximately 30% of the maximal response (EC~30~) (5-HT~3A~R: 0.5 *µ*M, 5-HT~3AB~R: 2 *µ*M). Both traces in [Fig. 2A](#F2){ref-type="fig"} show representative current responses at −60 mV. The first inward current represents the control current evoked by 5-HT alone, and this is followed by subsequent currents obtained by the coapplication of 5-HT (EC~30~) and increasing concentrations of bupropion, which dose-dependently inhibited 5-HT-induced currents for 5-HT~3A~ and 5-HT~3AB~ receptors. IC~50~ values were 87.1 *µ*M (*n*~H~ = 1.28 ± 0.15, *n* = 5) and 840 *µ*M (*n*~H~ = 1.78 ± 0.15, *n* = 7) for A and AB, respectively ([Fig. 2B](#F2){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Bupropion's potency at 5-HT~3AB~R was 10-fold lower when compared with 5-HT~3A~R (unpaired *t* test, t(10) = 8.49, *P* = 6.99 × 10^−6^). Bupropion alone did not elicit an inward current for either receptor ([Fig. 2C](#F2){ref-type="fig"}).

![Bupropion's antagonistic activity at homomeric and heteromeric 5-HT~3~Rs. (A) Sample traces of oocytes expressing 5-HT~3A~ or 5-HT~3AB~ in response to 5-HT (∼EC~30~) alone and in combination with bupropion. 5-HT--evoked inward currents (gray, 5-HT~3A~ = 0.3 μM, 5-HT~3AB~ = 2 μM) were used for the control current. Following, the 5-HT concentration was kept constant and coapplied with increasing concentrations of bupropion (5-HT~3A~: 10--1000 μM, 5-HT~3AB~: 30--4000 μM). (B) Currents were normalized to the control currents and yielded the following IC~50~ values: 5-HT~3A~: IC~50~ = 87.1 *µ*M (n~H~ = 1.28 ± 0.15, *n* = 5, mean ± S.D.) and 5-HT~3AB~: IC~50~ = 840 *µ*M (n~H~ = 1.78 ± 0.15, *n* = 7, mean ± S.D.). (C) Oocytes expressing 5-HT~3A~ and 5-HT~3AB~ did not elicit an inward current in response to bupropion alone.](mol.119.118349f2){#F2}

### Effect of Hydroxybupropion on 5-HT~3A~R and 5-HT~3AB~R. {#s13}

Hydroxybupropion, a major metabolite of bupropion, is known to contribute to the biologic efficacy of the parent drug because it also inhibits dopamine/norepinephrine transporters, nAChRs, and 5-HT~3A~Rs ([@B7]; [@B13]; [@B45]). Similar to bupropion, hydroxybupropion inhibited 5-HT~3A~Rs and 5-HT~3AB~Rs dose-dependently when coapplied with 5-HT ([Fig. 3A](#F3){ref-type="fig"}). The hydroxybupropion concentrations that reduced the 5-HT--evoked currents to 50% of the initial response were 113 *µ*M (*n* = 5, *n*~H~ = 1.17 ± 0.14) for 5-HT~3A~Rs and 526 *µ*M (*n* = 8, *n*~H~ = 1.80 ± 0.16) for 5-HT~3AB~Rs ([Fig. 3B](#F3){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Similar to bupropion, the potency of hydroxybupropion for 5-HT~3AB~Rs was right-shifted, resulting in a higher IC~50~ value as compared to 5-HT~3A~Rs (unpaired t, t(11) = 28.9, *P* = 1.01 × 10^−11^). Hydroxybupropion did not elicit a response in 5-HT~3A~ or 5-HT~3AB~ expressing oocytes when applied alone ([Fig. 3C](#F3){ref-type="fig"}).

![Hydroxybupropion is an antagonist for 5-HT~3A~Rs and 5-HT~3AB~Rs. (A) Sample traces of oocytes expressing 5-HT~3A~ or 5-HT~3AB~ in response to 5-HT (∼EC~30~) alone and in combination with hydroxybupropion. 5-HT--evoked inward currents (gray, 5-HT~3A~ = 0.3 μM, 5-HT~3AB~ = 2 μM) were used for the control current. Following, the 5-HT concentration was kept constant and coapplied with increasing concentrations of hydroxybupropion (5-HT~3A~: 10--1000 μM, 5-HT~3AB~: 50--2000 μM). (B) Currents were normalized to the control currents and yielded the following IC~50~ values: 5-HT~3A~: IC~50~ = 113 *µ*M (n~H~ = 1.17 ± 0.15, *n* = 5, mean ± S.D.) and 5-HT~3AB~: IC~50~ = 526 *µ*M (n~H~ = 1.80 ± 0.16, *n* = 8, mean ± S.D.). (C) Oocytes expressing 5-HT~3A~ and 5-HT~3AB~ did not elicit an inward current in response to hydroxybupropion alone.](mol.119.118349f3){#F3}

### Effect of Preincubation with Bupropion and Hydroxybupropion on 5-HT~3A~ and 5-HT~3AB~ Receptors. {#s14}

Bupropion's allosteric inhibition of 5-HT~3A~Rs is not dependent on the opening of the receptor's channel; it is non--use dependent ([@B45]). To evaluate the extent of inhibition evoked by preincubating oocytes expressing 5-HT~3A~ and 5-HT~3AB~Rs with bupropion or its metabolite, results were compared to the current amplitudes resulting from coapplication of 5-HT and bupropion/hydroxybupropion. First, oocytes were perfused with 5-HT (∼EC~30~, 5-HT~3A~R: 0.5 μM, 5-HT~3AB~R: 2 μM) and bupropion (∼IC~50~, 5-HT~3A~R: 100 μM, 5-HT~3AB~R: 1 mM) to obtain the control current ([Fig. 4A](#F4){ref-type="fig"}). Once a stable response was achieved, a constant IC~50~ concentration of bupropion was exposed to the receptors for exactly 5 min before another coapplication of the same 5-HT and bupropion solutions. Preincubation decreased the current amplitude of 5-HT~3A~Rs to 76.2% ± 7.16% ([Fig. 4C](#F4){ref-type="fig"}, left panel) of control, consistent with previous findings ([@B45]). On the contrary, under the same experimental conditions, the 5-HT~3AB~R was greatly affected by preincubation, which resulted in a current amplitude reduced to 35.5% ± 5.62% of the control current ([Fig. 4C](#F4){ref-type="fig"}, right panel). Similar results were obtained from preincubation with hydroxybupropion ([Fig. 4B](#F4){ref-type="fig"}). Compared with coapplication alone, preapplication resulted in a greater depression of current for 5-HT~3A~Rs and 5-HT~3AB~Rs with hydroxybupropion ([Fig. 4C](#F4){ref-type="fig"}, 5-HT~3A~R: 93.0% ± 6.12% and 5-HT~3AB~R: 46.1% ± 4.95% of control current).

![Non--use dependent allosteric inhibition of 5-HT~3A~Rs and 5-HT~3AB~Rs. (A) Sample traces of oocytes expressing 5-HT~3A~ (black, left panel) and 5-HT~3AB~ (green, right panel). The first 5-HT--evoked currents were used for the control currents (gray bars, ∼EC~30~, 5-HT~3A~: 0.5 *µ*M, 5-HT~3AB~: 2 *µ*M) that were obtained by coapplication with bupropion (magenta bars, ∼IC~50~, 5-HT~3A~: 100 *µ*M, 5-HT~3AB~: 1 mM). Following the stable 5-HT response, bupropion (∼EC~50~) was perfused for 5 min before another coapplication of 5-HT and bupropion. (B) Same experimental design as in (A) but with hydroxybupropion (blue bars, ∼IC~50~, 5-HT~3A~: 100 *µ*M, 5-HT~3AB~: 500 *µ*M). (C) Quantification of fractional inhibition of currents when the oocyte was preincubated in bupropion (magenta) or hydroxybupropion (blue) normalized to the control current (100%). Preincubation reduced current amplitudes for 5-HT~3A~ (Bup: 76.1% ± 7.16%, *n* = 5; HydroB: 93.0% ± 6.12%, *n* = 6) and 5-HT~3AB~ (Bup: 35.5% ± 5.62%, *n* = 6; HydroB: 46.1% ± 4.95%, *n* = 4) as compared with coapplication. Statistical significance was determined with paired *t* test (\**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001), comparing coapplication (representing 100% of the current) to preapplication + coapplication (Pre+Co) with each drug independently. Data are represented as the mean ± S.D.](mol.119.118349f4){#F4}

### Recovery Times for Bupropion Inhibition. {#s15}

Bupropion's antagonistic effect on 5-HT--evoked inward currents has been shown to be reversible ([@B45]). To evaluate the recovery times of bupropion's inhibition of 5-HT--induced currents at homomeric and heteromeric receptors, bupropion was applied to the oocytes for 60 s at a 400 μM concentration. For these experiments, the ∼EC~50~ concentration of 5-HT (gray bars, 5-HT~3A~R: 0.8 μM, 5-HT~3AB~R: 5.0 μM) was applied episodically after washing in between each application (∼2 min). These agonist-induced currents led to minimal run-down, and the difference in current amplitudes was less than 10% ([Fig. 5A](#F5){ref-type="fig"}). Sample traces of current recovery following bupropion application and removal are shown in [Fig. 5B](#F5){ref-type="fig"} (left: black, 5-HT~3A~R, right: green, 5-HT~3AB~R). The first current response is the control current evoked by the agonist alone. Once a stable current response was obtained, bupropion was applied without the agonist for 60 s (magenta bars). Subsequently, the agonist was either applied immediately or after 10, 30, or 60 s ([Fig. 5B](#F5){ref-type="fig"}, top trace: 0 s, middle: 30 s, bottom: 60 s) after bupropion exposure. The largest decrease in current amplitude for both receptors was immediately after the bupropion application, leaving 82.4% ± 3.08% and 38.4% ± 15.8% of the initial current for A and AB, respectively ([Fig. 5C](#F5){ref-type="fig"}). Rapid recovery of current amplitude was achieved by increasing the wash times between bupropion and 5-HT applications. 5-HT~3A~Rs and 5-HT~3AB~Rs both show time-dependent recovery from bupropion inhibition with full reversal after 7+ min wash time.

![Recovery times for bupropion. (A and B) Sample traces of bupropion application (magenta bar) and the recovery times for 5-HT~3A~ (left panel, black) and 5-HT~3AB~ (right panel, green). (A) In two-electrode voltage clamp experiments, oocytes expressing 5-HT~3A~ and 5-HT~3AB~ showed a stable response to repeated applications of 0.8 and 5 μM 5-HT at −60 mV, with an approximate wash time of 2 min. (B) The first 5-HT--evoked response represents the control current for the recovery experiment. Bupropion (400 μM) was applied alone for 60 s at −60 mV, followed by an immediate application of 5-HT. The gray and magenta bars represent the time of application of 5-HT and bupropion, respectively. Moving down the panel, the wash times after bupropion application were 0, 30, and 60 s. (C) Quantitative representation of current amplitudes and results in (B) (*n* = 3). 5-HT~3A~ was maximally reduced to 82.4% ± 3.08% and 5-HT~3AB~ to 38.4% ± 15.8% of the control current when the agonist was applied immediately after bupropion, followed by a stepwise recovery. All currents could be recovered to ∼95% after ∼7.5-min wash. Statistical significance of each wash time as compared with the control current (the 5-HT--induced current response before exposure to Bup or HydroB) was determined with one-way ANOVA, Dunnett's multiple comparisons test (\**P* ≤ 0.05; \*\*\**P* ≤ 0.001). Data are represented as the mean ± S.D.](mol.119.118349f5){#F5}

### Voltage-Independent Binding of Bupropion. {#s16}

To determine if bupropion binds to 5-HT~3~Rs in a voltage-dependent manner, 5-HT--induced currents (∼EC~50~; 5-HT~3A~R: 0.8 *µ*M; 5-HT~3AB~R: 5.0 *µ*M) were evoked in oocytes expressing 5-HT~3A~Rs and 5-HT~3AB~Rs at two different holding potentials, +40 and −40 mV ([Fig. 6A](#F6){ref-type="fig"}). First, the control current was obtained at positive and negative voltages before the coapplication of 5-HT and bupropion (∼IC~50~; 5-HT~3A~R: 100 *µ*M; 5-HT~3AB~R: 1 mM). Bupropion reduced the current amplitudes of homomeric and heteromeric receptors at both voltages. The mean fractional block was recorded at each voltage and normalized to the control current ([Fig. 6B](#F6){ref-type="fig"}; 5-HT~3A~R: 55.8% ± 0.11%, 59.8% ± 0.10%; 5-HT~3AB~R: 56.6% ± 0.04%, 59% ± 0.08%; −40 and +40 mV, respectively, *n* = 4). For 5-HT~3A~R and 5-HT~3AB~R, this fractional inhibition is similar at positive and negative voltages (paired *t* test, 3A: t(3) = 1.106, *P* = 0.349; 3AB: t(3) = 0.291, *P* = 0.790). Based on these results, inhibition of 5-HT--induced currents by bupropion is independent of voltage.

![Voltage-independent block of 5-HT~3~--mediated currents by bupropion. (A) Sample traces of 5-HT~3A~-- and 5-HT~3AB~--expressing oocytes (5-HT~3A~: left, black; 5-HT~3AB~: right, green) in response to 5-HT (∼EC~50~; top and bottom traces, 5-HT~3A~: 0.8 *µ*M; 5-HT~3AB~: 5.0 *µ*M) in the absence and presence of bupropion (magenta traces, ∼IC~50~; 5-HT~3A~: 100 *µ*M; 5-HT~3AB~: 1 mM) at different voltages. (B) Quantification of fractional inhibition, currents were normalized to the control currents at each voltage (*n* = 4). Data are shown as mean ± S.D. Statistical significance between the inhibition at positive and negative voltages was determined with paired *t* test (\**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001).](mol.119.118349f6){#F6}

### Bupropion at Physiologic Concentrations and Its Effect on 5-HT~3A~R and 5-HT~3AB~R. {#s17}

To better understand the clinical significance of the bupropion-induced inhibition of 5-HT~3~Rs, 5-HT--induced currents were measured in the presence of a clinically relevant bupropion concentration \[∼20 *µ*M ([@B49]; [@B56])\]. First, oocytes expressing 5-HT~3A~Rs and 5-HT~3AB~Rs were exposed to three different 5-HT concentrations (0.5, 1.0, 5.0 *µ*M) in the absence of bupropion to obtain the initial current amplitudes ([Fig. 7A](#F7){ref-type="fig"}, black, left panel: 5-HT~3A~R, green, right panel: 5-HT~3AB~R). Next, the oocytes were continuously perfused with 20 *µ*M bupropion, and the same 5-HT concentrations were reapplied; the oocytes were preincubated with bupropion for at least 2 minprior to 5-HT application ([Fig. 7A](#F7){ref-type="fig"}, magenta bars indicating bupropion presence). The results indicate that the continuous presence of a low concentration of bupropion in the bath solution partially inhibits 5-HT--induced currents of 5-HT~3A~Rs and 5-HT~3AB~Rs at all 5-HT concentrations tested ([Fig. 7B](#F7){ref-type="fig"}, paired *t* test, *P* ≤ 0.05 or lower). Bupropion inhibited 5-HT--induced currents by ∼18% for 5-HT~3A~Rs (*n* = 4), whereas 5-HT~3AB~Rs showed a ∼23% decrease in current (*n* = 5, [Fig. 7B](#F7){ref-type="fig"}).

![Bupropion at clinically achievable concentrations and its effect on 5-HT~3A~Rs and 5-HT~3AB~Rs. (A) Sample traces of oocytes expressing 5-HT~3A~ (black, left panel) and 5-HT~3AB~ (green, right panel) in response to 0.5, 1.0, and 5.0 μM 5-HT (gray bars) followed by the same concentrations coapplied with 20 μM bupropion. Following the initial exposure to the three 5-HT concentrations (control current), the oocytes were exposed to 20 μM bupropion for at least 2 min before coapplication with the agonist. (B) Quantitative representation of current amplitudes and results in (A) (A: *n* = 4, AB: *n* = 5). Data are shown as mean ± S.D. Statistical significance between each 5-HT concentration without and with bupropion at the same 5-HT concentration was determined with paired *t* test (\**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001).](mol.119.118349f7){#F7}
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Our results, for the first time, demonstrate that bupropion antagonizes heteromeric 5-HT~3AB~ receptors and that the kinetics of inhibition are distinct from 5-HT~3A~. Two-electrode voltage clamp experiments indicate that bupropion reversibly inhibits 5-HT--induced currents of *Xenopus* oocytes expressing 5-HT~3A~ and 5-HT~3AB~Rs in a concentration-dependent manner, with inhibitory potencies of 87.1 μM \[same as previously reported ([@B45])\] and 840 μM, respectively. Similar to other noncompetitive antagonists \[such as picrotoxin ([@B14])\], bupropion has a lower potency (∼10-fold) at 5-HT~3AB~ as compared to 5-HT~3A~ receptors and, therefore, could be used to discriminate between these two receptors ([@B54]).

Similarly to bupropion, the metabolite inhibits nAChRs and 5-HT~3A~Rs in a noncompetitive manner ([@B13]; [@B45]) and also shares a comparable potency (unpaired *t* test, *P* value = 0.06704) for the homomeric receptor \[5-HT~3A~R: IC~50~ = 113 μM, similar to previously reported data ([@B45])\]. Hydroxybupropion exhibits a ∼4.5-fold shift in IC~50~ for the heteromeric channel (5-HT~3AB~R: IC~50~ = 526 μM). The estimated Hill slopes (*n*~H~ values) for both bupropion and hydroxybupropion for both receptors were greater than unity (1.17--1.80), suggesting the presence of multiple binding sites with a cooperative mechanism. The Hill coefficients for the 5-HT~3AB~R were ∼1.4 times larger for both bupropion and hydroxybuporpion as compared with for the 5-HT~3A~R, which may indicate a concerted conformational change or cooperativity of binding ([@B11]).

Bupropion-mediated inhibition of 5-HT~3A~Rs is non--use dependent ([@B45]). In general, use-dependent block, or inhibition that would require a channel to be open to occur, is not influenced by preapplication. We evaluated the effect of a 5-min preincubation with bupropion and its metabolite hydroxybupropion on the homomeric and the heteromeric receptor ([Fig. 4](#F4){ref-type="fig"}). Preincubation with antagonistled to an increased inhibition in all cases when compared with coapplication, indicating that the block is non--use dependent for both receptors. Our observation that bupropion's inhibition of 5-HT~3~Rs is voltage-independent additionally concurs with it not acting as an open channel blocker ([@B50]; [@B10]; [@B25]). Similar results are shown with other antidepressants at 5-HT~3~Rs ([@B18]) and with bupropion at nAChRs (e.g., *α*~3~*β*~2~, *α*~4~*β*~2~, *α*~3~*β*~4~) with predictions for an external binding site for bupropion ([@B50]; [@B23]). Considering different binding sites within the family of AChRs ([@B44]), bupropion may have distinct binding sites in each channel ([@B3]).

We saw a greater depression of current amplitudes when bupropion or its metabolite was preincubated as compared with coapplication with 5-HT \[[Fig. 5](#F5){ref-type="fig"}, 5-HT~3A~R: 76.2% ± 7.16%, 93.0% ± 6.12%; 5-HT~3AB~R: 35.5% ± 5.62%, 46.1% ± 4.95% of control current, Bup and HydroB, respectively\]. During the preincubation experiments, bupropion binds and inhibits the receptor prior to the opening of the channel, therefore presumably interacting with the closed channel and potentially inhibiting the channel from opening ([@B10]; [@B3]). Consistent with other data, greater potencies of inhibition have been reported for bupropion and tricyclic antidepressants on Cys-loop receptors in the resting state than the open state ([@B10]; [@B26]; [@B3]). This phenomenon may be due to the accumulation of antidepressants and antipsychotics in the cell membrane during preincubation, which may be important for the functional antagonistic effects of these drugs at the 5-HT~3~ receptor ([@B19]). Overall, this may indicate that bupropion has access to its binding site(s) from the membrane environment. We find that inhibition after preincubation is more pronounced in the 5-HT~3AB~ as compared with the 5-HT~3A~ receptor.

Bupropion's inhibition of 5-HT--mediated currents is reversible after a substantial amount of washing. In this study, we investigated the time it takes for 5-HT~3~R to recover from preincubation with bupropion at high concentrations (400 *µ*M Bup). Similar to our preincubation experiments, bupropion reduced 5-HT~3A~R currents but to a lesser extent than 5-HT~3AB~R currents. The largest reduction of current was observed with the shortest amount of wash time between the bupropion and agonist applications (5-HT~3A~R: 82.4% ± 3.08%; 5-HT~3AB~R: 38.4% ± 15.8% of the control current after 0-s wash). 5-HT~3A~ and 5-HT~3AB~ receptors show a time-dependent recovery from bupropion's inhibition, and their currents could be fully recovered after ∼7.5 min of washing.

The clinical relevance of 5-HT~3~ inhibition by bupropion is currently unknown. Bupropion, but not its metabolites, concentrates in many tissues with a brain to plasma ratio of 25:1 ([@B49]), which results in brain concentrations of ∼20 *µ*M ([@B56]). Coapplication of 20 μM bupropion with agonist minimally inhibits 5-HT--induced currents of 5-HT~3A~Rs and does not affect HT~3AB~Rs. On the contrary, preincubation with bupropion has a drastic impact on its inhibitory effect ([Fig. 7](#F7){ref-type="fig"}). Our results indicate that a preincubation time of 5 min with 20 *µ*M bupropion is enough to inhibit 5-HT~3~ receptors (5-HT~3A~R: ∼82.7% 5-HT~3AB~R: ∼74.9% of control current). Moreover, hydroxybupropion reaches ∼10-fold higher plasma concentrations in humans as compared with the parent drug ([@B22]; [@B28]). With an average of ∼100 *µ*M (based on clinical data, test ID: FBUMT; Mayo Clinic, MN), hydroxybupropion's plasma concentrations are equivalent to 5-HT~3A~R's IC~50~ value. Additionally, considering the increased inhibitory effect due to preincubation of 5-HT~3~Rs, we conclude that bupropion and hydroxybupropion have the potential to inhibit these receptors at clinically attainable concentrations.

The comprehensive mechanism by which bupropion achieves its therapeutic efficacy is multifactorial. At therapeutic dosages, bupropion inhibits nACh receptors in the ventral tegmental area, dorsal raphe nucleus neurons, and interneurons in the hippocampal CA1 area ([@B1]; [@B56]). There, nAChRs can modulate serotonergic projections ([@B4]; [@B9]) and alter GABAergic transmission ([@B31]), in turn increasing dopamine levels, contributing to bupropion's antidepressant activity ([@B2]; [@B56]). 5-HT~3~ receptors also show strong interactions with GABAergic neurons in the hippocampus and neocortical cells ([@B41]) and mediate stress-dependent activation of dopaminergic neurotransmission ([@B16]; [@B6]). Animal studies have demonstrated that 5-HT~3~ antagonists have anxiolytic activity, possibly because of the inhibition of limbic hyperactivity responses ([@B6]), and this is supported by the finding that 5-HT~3A~R gene deletion produces an anxiolytic phenotype in mice ([@B33]). Furthermore, 5-HT~3~ antagonists have implications on hippocampal long-term potentiation ([@B5]), increase synaptic norepinephrine levels, facilitate 5-HT neurotransmission of other 5-HT receptors ([@B46]), and even enhance the antidepressant action of bupropion ([@B16]).

In conclusion, 5-HT~3~ and nACh receptors have shown many implications in the neurobiology of depression and a highly complex interplay can be expected between these systems. Currently, it is not known if bupropion- or hydroxybupropion-mediated inhibition of 5-HT~3~ receptors is clinically relevant for their antidepressant activity. Further studies focused on characterizing bupropion's accumulation in membranes, identification of its binding sites, and delineation of its molecular mechanism of action are warranted. We show here that bupropion inhibits 5-HT~3~ receptors at clinically relevant concentrations and that this inhibition may contribute to bupropion's clinical effects.
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5-HT

:   serotonin

5-HT~3~R

:   5-HT type 3 receptor

5-HT~3A~R

:   5-HT type 3A receptor

5-HT~3AB~R

:   5-HT type 3AB receptor

Bup

:   bupropion

cRNA

:   complementary RNA

EC~30~

:   concentration that elicits approximately 30% of the maximal response

HydroB

:   hydroxybupropion

nACh

:   nicotinic acetylcholine

nAChR

:   nACh receptor

OR-2

:   oocyte ringer solution
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